Page last updated: 2024-12-08

alpha-D-fructofuranose 1,6-bisphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alpha-D-fructofuranose 1,6-bisphosphate : A D-fructofuranose 1,6-bisphosphate with an alpha-configuration at the anomeric position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445557
CHEMBL ID1089962
CHEBI ID40595
SCHEMBL ID166666

Synonyms (21)

Synonym
.alpha.-d-fructofuranose 1,6-diphosphate
nsc-57553
alpha-d-fructofuranose 1,6-bisphosphate
alpha fructose 1,6-diphosphate
CHEBI:40595 ,
1,6-di-o-phosphono-alpha-d-fructofuranose
alpha-d-fructofuranose 1,6-bis(dihydrogen phosphate)
CHEMBL1089962 ,
bdbm50420197
SCHEMBL166666
alpha-fructose-1,6-diphosphate
RNBGYGVWRKECFJ-ZXXMMSQZSA-N
.alpha.-d-fructofuranose, 1,6-bis(dihydrogen phosphate)
alpha-d-fructofuranose 1,6-diphosphate
ANW5CM3PJ7 ,
alpha-d-fructofuranose, 1,6-bis(dihydrogen phosphate)
unii-anw5cm3pj7
alpha-d-fosfructofuranose
Q27104462
alpha-d-fructofuranose 1,6-bisphosphate (rsss closed ring)
.alpha.-d-fosfructofuranose
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
D-fructofuranose 1,6-bisphosphateThe furanose form of D-fructose 1,6-bisphosphate.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (31)

PathwayProteinsCompounds
Glycolysis1423
Gluconeogenesis2232
Fructose and Mannose Degradation1830
Pentose Phosphate Pathway1527
Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease2232
Glucose-6-phosphate Dehydrogenase Deficiency1527
Ribose-5-phosphate Isomerase Deficiency1527
Transaldolase Deficiency1527
Glycogenosis, Type VII. Tarui Disease1423
Phosphoenolpyruvate Carboxykinase Deficiency 1 (PEPCK1)2232
Fructosuria1830
Fructose-1,6-diphosphatase Deficiency2232
Triosephosphate Isomerase Deficiency2232
Fanconi-Bickel Syndrome1423
Glycogenosis, Type IB2232
Glycogenosis, Type IC2232
Glycogenosis, Type IA. Von Gierke Disease2232
Warburg Effect4652
Fructose Intolerance, Hereditary1830
Glycolysis and Pyruvate Dehydrogenase2428
Gluconeogenesis from L-Malic Acid2024
Fructose Metabolism1520
Glycerol Metabolism3028
Glycerol Metabolism II2930
Glycerol Metabolism III (sn-Glycero-3-Phosphoethanolamine)3030
Glycerol Metabolism IV (Glycerophosphoglycerol)3030
Glycerol Metabolism V (Glycerophosphoserine)3030
Glycolysis I1023
Ethanol Fermentation1527
Photosynthesis6324
Calvin-Benson Cycle1321

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier organic anion transporter family member 2A1Homo sapiens (human)Ki51,000.00000.02300.07000.1490AID681570
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
26S proteasome non-ATPase regulatory subunit 1Rattus norvegicus (Norway rat)Activity0.08000.08000.08000.0800AID705459
Pyruvate kinase PKMHomo sapiens (human)Activity0.08000.08000.08000.0800AID705459
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
lipid transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
lipid transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
lysosomeSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 2A1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID681570TP_TRANSPORTER: inhibition of PGE2 uptake in PGT-expressing HeLa cells2002American journal of physiology. Renal physiology, Jun, Volume: 282, Issue:6
Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT.
AID705459Activation of human pyruvate kinase M2 using phosphoenolpyruvate as substrate assessed as concentration required for 50% activation by kinaseGlo assay2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482990Activation of human PKM2 assessed as reduction of Vmax for phosphoenolpyruvate2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482991Activation of human PKM2 assessed as effect on Km for ADP2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID476499Activation of PKM2 assessed as reduction of Km for phosphoenolpyruvate relative to untreated control2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID705458Activation of human pyruvate kinase M2 using phosphoenolpyruvate as substrate by kinaseGlo assay relative to control2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID482989Activation of human PKM2 assessed as reduction of Km for phosphoenolpyruvate2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID476500Activation of PKM2 in presence of excess of phosphoenolpyruvate level2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]